Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Robert A. Copeland, Ph.D., has been named President of Research. Dr. Copeland, who was previously Executive Vice President of Research and Chief Scientific Officer at Epizyme, will continue to serve as Chief Scientific Officer.
Help employers find you! Check out all the jobs and post your resume.
